Module 4: Optimizing outcomes in spasticity treatment

With many recent advancements in spasticity treatment, more patients are surviving critical illness and injury but are left with ongoing disability that needs constant treatment. Such treatment will change as the patient's condition evolves. Constant appraisal of treatment efficacy and patient progress is therefore an important component of spasticity management, and physicians need to be familiar with how to troubleshoot treatment regimens when outcomes of that regimen become suboptimal. This module considers how to optimize the use and outcomes of major treatment modalities and provides drug and device maintenance algorithms to guide the treating team.

[1]  A. Esquenazi,et al.  Patient Perspectives on the Therapeutic Profile of Botulinum Neurotoxin Type A in Spasticity , 2020, Frontiers in Neurology.

[2]  D. Dressler,et al.  Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy , 2020, Neurology.

[3]  H. Hefter,et al.  High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy , 2018, Neurology.

[4]  K. Fheodoroff,et al.  An international survey of patients living with spasticity , 2017, Disability and rehabilitation.

[5]  A. Esquenazi,et al.  Poster 312 Muscle Selection Patterns for Injection of OnabotulinumtoxinA in Adult Patients with Post‐Stroke Lower‐Limb Spasticity Influence Outcome: Results from a Double‐Blind, Placebo‐Controlled Phase 3 Clinical Trial , 2016, PM & R : the journal of injury, function, and rehabilitation.

[6]  David J. Anderson,et al.  Best Practices for Intrathecal Baclofen Therapy: Troubleshooting , 2016, Neuromodulation : journal of the International Neuromodulation Society.

[7]  J. Jankovic,et al.  Long-Term Efficacy and Safety of Botulinum Toxin Injections in Dystonia , 2013, Toxins.

[8]  S. Henly,et al.  Understanding spasticity from patients' perspectives over time. , 2012, Journal of advanced nursing.

[9]  D. Stokic,et al.  Effect of concentration and mode of intrathecal baclofen administration on soleus H-reflex in patients with muscle hypertonia , 2012, Clinical Neurophysiology.

[10]  Matthew A. Brodsky,et al.  Diffusion of Botulinum Toxins , 2012, Tremor and other hyperkinetic movements.

[11]  A. Pickett Consistent Biochemical Data are Essential for Comparability of Botulinum Toxin Type A Products , 2011, Drugs in R&D.

[12]  M. Turner Assessing Syndromes of Catheter Malfunction With SynchroMed Infusion Systems: The Value of Spiral Computed Tomography With Contrast Injection , 2010, PM & R : the journal of injury, function, and rehabilitation.

[13]  Kenneth Ngo,et al.  Poster 45: Failure to Identify Intrathecal Baclofen Pump/Catheter Problems Can Lead to Unnecessary Healthcare Costs: A Case Report , 2009 .

[14]  S. Dodd,et al.  Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications , 2008, Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology.

[15]  A. Marchetti,et al.  Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review. , 2000, Clinical therapeutics.

[16]  C. Sampaio,et al.  DYSBOT: A single‐blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1 , 1997, Movement disorders : official journal of the Movement Disorder Society.

[17]  I. Sanders,et al.  Quantifying how location and dose of botulinum toxin injections affect muscle paralysis , 1993, Muscle & nerve.

[18]  I. Baguley,et al.  Goal attainment scaling in the evaluation of treatment of upper limb spasticity with botulinum toxin: a secondary analysis from a double-blind placebo-controlled randomized clinical trial. , 2010, Journal of rehabilitation medicine.

[19]  W. Herzog,et al.  Botox produces functional weakness in non-injected muscles adjacent to the target muscle. , 2008, Journal of biomechanics.